Published in

Elsevier, Best Practice and Research: Clinical Haematology, 1(22), p. 49-60, 2009

DOI: 10.1016/j.beha.2008.12.009

Links

Tools

Export citation

Search in Google Scholar

Procoagulant mechanisms in tumour cells

Journal article published in 2009 by Anna Falanga, Marina Panova-Noeva, Laura Russo ORCID
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Pathogenesis of the prothrombotic state of cancer patients is due, at least in part, to the ability of cancer cells to activate the coagulation system. Several complex and not fully recognized interactions between the malignant cell and the clotting system promote a shift in the haemostatic balance compared with a procoagulant state. Tumour cells possess the capacity to interact with the haemostatic system in multiple ways. The principal mechanisms include the expression of haemostatic proteins by tumour cells, the production of inflammatory cytokines by tumour and/or host cells, and the direct adhesion of tumour cells to normal cells, including platelets, endothelial cells and monocytes. This chapter will summarize the prothrombotic mechanisms of tumour cells and their role in both coagulation and tumour progression. In particular, this chapter will focus on the capacity of tumour cells to promote activation of the coagulation system, and on the mechanisms by which clotting proteins may promote tumour growth and metastasis.